ArticleBriefings in bioinformatics2025
GEMDiff: a diffusion workflow bridges between normal and tumor gene expression states: a breast cancer case study.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enhancing Doxorubicin Bioavailability via Dissolving Microneedles: Roles of Drug Loading and Administration Force.AAPS PharmSciTech · 2026Article
- Artificial Intelligence-Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance.Journal of multidisciplinary healthcare · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breast cancer remains a significant global health challenge due to its complexity, which arises from multiple genetic and epigenetic mutations that originate in normal breast tissue. Traditional machine learning models often fall short in addressing the intricate gene interactions that complicate drug design and treatment strategies. In contrast, our study introduces GEMDiff, a novel computational workflow leveraging a diffusion model to bridge the gene expression states between normal and tumor conditions. GEMDiff augments RNAseq data and simulates perturbation transformations between normal and tumor gene states, enhancing biomarker identification. GEMDiff can handle large-scale gene expression data without succumbing to the scalability and stability issues that plague other generative models. By avoiding the need for task-specific hyper-parameter tuning and specific loss functions, GEMDiff can be generalized across various tasks, making it a robust tool for gene expression analysis. The model's ability to augment RNA-seq data and simulate gene perturbations provides a valuable tool for researchers. This capability can be used to generate synthetic data for training other machine learning models, thereby addressing the issue of limited biological data and enhancing the performance of predictive models. The effectiveness of GEMDiff is demonstrated through a case study using breast mRNA gene expression data, identifying 307 core genes involved in the transition from a breast tumor to a normal gene expression state. GEMDiff is open source and available at https://github.com/xai990/GEMDiff.git under the MIT license.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.